Baker Bros. Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $487M | Hold |
5,604,483
| – | – | 2.8% | 12 |
|
|
2025
Q4 | $600M | Hold |
5,604,483
| – | – | 3.51% | 10 |
|
|
2025
Q3 | $566M | Hold |
5,604,483
| – | – | 4.09% | 7 |
|
|
2025
Q2 | $354M | Hold |
5,604,483
| – | – | 3.44% | 7 |
|
|
2025
Q1 | $297M | Sell |
5,604,483
-479,766
| -8% | -$26.6M | 3.29% | 7 |
|
|
2024
Q4 | $341M | Sell |
6,084,249
-314,117
| -5% | -$17.4M | 3.64% | 8 |
|
|
2024
Q3 | $335M | Buy |
6,398,366
+1
| +0% | +$48 | 3.47% | 7 |
|
|
2024
Q2 | $263M | Hold |
6,398,365
| – | – | 3.36% | 6 |
|
|
2024
Q1 | $277M | Hold |
6,398,365
| – | – | 3.48% | 5 |
|
|
2023
Q4 | $294M | Sell |
6,398,365
-303,984
| -5% | -$9.59M | 3.35% | 5 |
|
|
2023
Q3 | $154M | Buy |
6,702,349
+204,082
| +3% | +$4.57M | 0.89% | 7 |
|
|
2023
Q2 | $107M | Hold |
6,498,267
| – | – | 0.62% | 12 |
|
|
2023
Q1 | $116M | Buy |
6,498,267
+143,659
| +2% | +$3.61M | 0.63% | 8 |
|
|
2022
Q4 | $185M | Buy |
6,354,608
+291,906
| +5% | +$7.5M | 1.11% | 8 |
|
|
2022
Q3 | $149M | Buy |
6,062,702
+1,937,640
| +47% | +$36M | 0.97% | 9 |
|
|
2022
Q2 | $17.1M | Hold |
4,125,062
| – | – | 0.1% | 53 |
|
|
2022
Q1 | $47.5M | Buy |
4,125,062
+261,823
| +7% | +$2.3M | 0.27% | 29 |
|
|
2021
Q4 | $38.6M | Hold |
3,863,239
| – | – | 0.19% | 40 |
|
|
2021
Q3 | $50.5M | Hold |
3,863,239
| – | – | 0.22% | 36 |
|
|
2021
Q2 | $75.6M | Buy |
3,863,239
+383,366
| +11% | +$7.96M | 0.33% | 28 |
|
|
2021
Q1 | $74M | Buy |
3,479,873
+1,165,000
| +50% | +$33.8M | 0.32% | 29 |
|
|
2020
Q4 | $68.8M | Sell |
2,314,873
-156,282
| -6% | -$3.97M | 0.26% | 26 |
|
|
2020
Q3 | $53.5M | Sell |
2,471,155
-228,900
| -8% | -$5.25M | 0.21% | 29 |
|
|
2020
Q2 | $60.2M | Sell |
2,700,055
-8,145
| -0.3% | -$159K | 0.27% | 31 |
|
|
2020
Q1 | $41.2M | Hold |
2,708,200
| – | – | 0.25% | 29 |
|
|
2019
Q4 | $62.2M | Hold |
2,708,200
| – | – | 0.33% | 25 |
|
|
2019
Q3 | $58.5M | Hold |
2,708,200
| – | – | 0.4% | 20 |
|
|
2019
Q2 | $59.6M | Hold |
2,708,200
| – | – | 0.4% | 24 |
|
|
2019
Q1 | $74.2M | Hold |
2,708,200
| – | – | 0.48% | 21 |
|
|
2018
Q4 | $72.8M | Hold |
2,708,200
| – | – | 0.6% | 16 |
|
|
2018
Q3 | $79M | Hold |
2,708,200
| – | – | 0.52% | 19 |
|
|
2018
Q2 | $84.7M | Buy |
2,708,200
+659,180
| +32% | +$18M | 0.64% | 17 |
|
|
2018
Q1 | $40.8M | Hold |
2,049,020
| – | – | 0.35% | 28 |
|
|
2017
Q4 | $59.5M | Buy |
+2,049,020
| New | +$54.2M | 0.52% | 22 |
|
Other funds holding RYTM
RCM
VPM
VCM
PA
Baker Bros. Advisors's RYTM Position: Q1 2026 in Review
Baker Bros. Advisors held its Rhythm Pharmaceuticals (RYTM) position steady in Q1 2026 at 5,604,483 shares worth $487M. The position accounts for 2.8% of the portfolio, ranked #12.
Baker Bros. Advisors first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $600M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Baker Bros. Advisors held 5,604,483 shares of Rhythm Pharmaceuticals worth $487M as of Q1 2026.
- Baker Bros. Advisors left its Rhythm Pharmaceuticals share count unchanged in Q1 2026.
- Rhythm Pharmaceuticals made up 2.8% of Baker Bros. Advisors's portfolio in Q1 2026, its #12 holding.
- Baker Bros. Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Baker Bros. Advisors's Rhythm Pharmaceuticals position peaked at $600M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.